Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0XUHNE |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | KM8047 |
|||||
| Organization | Kyowa Kirin Co., Ltd.; Kyushu University. |
|||||
| Synonyms |
KM8047
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Undisclosed |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
KM8047-SG3249 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
495.3 ng/mL
|
High TIM-3 expression (TIM-3 +++) | ||
| Method Description |
EoL-1, EoL-1/hTIM-3 and Kasumi-3 cells were incubated with increasing concentrations of KK2845 or KM8047-SG3249 in RPMI1640 medium supplemented with 10 vol% (for EoL-1 and EoL-1/hTIM-3 cells) or 20 vol% (for Kasumi-3 cells) heat-inactivated fetal bovine serum, 20 vol% heat-inactivated human serum (Sigma), and a mixture of 100 U/mL penicillin and 100 ug/mL streptomycin at 37 °C for 4 days. After incubation, the cells were treated with Cell Counting Kit-8 (CCK-8, Dojindo Laboratories), and the absorbance was measured using a Multiskan Ascent device (Thermo Fisher Scientific, Ascent Software: version 2.6). Primary AML cells were incubated with increasing concentrations of KM8047-SG3249, KK2845, or CD33-ADC in IMDM medium (Thermo Fisher Scientific) supplemented with 20 vol% heat-inactivated human serum, a mixture of 100 U/mL penicillin and 100 ug/mL streptomycin, 25 ng/mL hIL-3 (Miltenyi Biotec), 25 ng/mL hSCF (Peprotech), 25 ng/mL hGM-CSF (R&D), and 25 ng/mL hG-CSF (R&D) at 37 °C for 4 days. After incubation, the cells were stained by anti-CD45 antibody-FITC (BD Pharmingen, HI30 clone), anti-CD34 antibody-APC (BD Bioscience, 8G12 clone), anti-CD38 antibody-BV421 (BD Bioscience, HIT2 clone) and 7-amino-actinomycin D (7-AAD, Bio-Rad Laboratories). The number of viable cells in the CD34+ fraction, CD34+CD38- fraction, or CD34- fraction in primary AML cells was counted by flow cytometry (FACSVerse, software program: BD FACSUITE-V1.0.5).
Click to Show/Hide
|
||||
| In Vitro Model | Chronic eosinophilic leukemia, not otherwise specified,Chronic eosinophilic leukemia | EoL-1/hTIM-3 cells | CVCL_0258 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
640.8 ng/mL
|
Low TIM-3 expression (TIM-3+) | ||
| Method Description |
EoL-1, EoL-1/hTIM-3 and Kasumi-3 cells were incubated with increasing concentrations of KK2845 or KM8047-SG3249 in RPMI1640 medium supplemented with 10 vol% (for EoL-1 and EoL-1/hTIM-3 cells) or 20 vol% (for Kasumi-3 cells) heat-inactivated fetal bovine serum, 20 vol% heat-inactivated human serum (Sigma), and a mixture of 100 U/mL penicillin and 100 ug/mL streptomycin at 37 °C for 4 days. After incubation, the cells were treated with Cell Counting Kit-8 (CCK-8, Dojindo Laboratories), and the absorbance was measured using a Multiskan Ascent device (Thermo Fisher Scientific, Ascent Software: version 2.6). Primary AML cells were incubated with increasing concentrations of KM8047-SG3249, KK2845, or CD33-ADC in IMDM medium (Thermo Fisher Scientific) supplemented with 20 vol% heat-inactivated human serum, a mixture of 100 U/mL penicillin and 100 ug/mL streptomycin, 25 ng/mL hIL-3 (Miltenyi Biotec), 25 ng/mL hSCF (Peprotech), 25 ng/mL hGM-CSF (R&D), and 25 ng/mL hG-CSF (R&D) at 37 °C for 4 days. After incubation, the cells were stained by anti-CD45 antibody-FITC (BD Pharmingen, HI30 clone), anti-CD34 antibody-APC (BD Bioscience, 8G12 clone), anti-CD38 antibody-BV421 (BD Bioscience, HIT2 clone) and 7-amino-actinomycin D (7-AAD, Bio-Rad Laboratories). The number of viable cells in the CD34+ fraction, CD34+CD38- fraction, or CD34- fraction in primary AML cells was counted by flow cytometry (FACSVerse, software program: BD FACSUITE-V1.0.5).
Click to Show/Hide
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1576.3 ng/mL
|
Low TIM-3 expression (TIM-3+) | ||
| Method Description |
EoL-1, EoL-1/hTIM-3 and Kasumi-3 cells were incubated with increasing concentrations of KK2845 or KM8047-SG3249 in RPMI1640 medium supplemented with 10 vol% (for EoL-1 and EoL-1/hTIM-3 cells) or 20 vol% (for Kasumi-3 cells) heat-inactivated fetal bovine serum, 20 vol% heat-inactivated human serum (Sigma), and a mixture of 100 U/mL penicillin and 100 ug/mL streptomycin at 37 °C for 4 days. After incubation, the cells were treated with Cell Counting Kit-8 (CCK-8, Dojindo Laboratories), and the absorbance was measured using a Multiskan Ascent device (Thermo Fisher Scientific, Ascent Software: version 2.6). Primary AML cells were incubated with increasing concentrations of KM8047-SG3249, KK2845, or CD33-ADC in IMDM medium (Thermo Fisher Scientific) supplemented with 20 vol% heat-inactivated human serum, a mixture of 100 U/mL penicillin and 100 ug/mL streptomycin, 25 ng/mL hIL-3 (Miltenyi Biotec), 25 ng/mL hSCF (Peprotech), 25 ng/mL hGM-CSF (R&D), and 25 ng/mL hG-CSF (R&D) at 37 °C for 4 days. After incubation, the cells were stained by anti-CD45 antibody-FITC (BD Pharmingen, HI30 clone), anti-CD34 antibody-APC (BD Bioscience, 8G12 clone), anti-CD38 antibody-BV421 (BD Bioscience, HIT2 clone) and 7-amino-actinomycin D (7-AAD, Bio-Rad Laboratories). The number of viable cells in the CD34+ fraction, CD34+CD38- fraction, or CD34- fraction in primary AML cells was counted by flow cytometry (FACSVerse, software program: BD FACSUITE-V1.0.5).
Click to Show/Hide
|
||||
| In Vitro Model | Adult acute myeloid leukemia | Kasumi-3 cells | CVCL_0612 | ||
References